ReviewJournal of neurology2022
Levodopa-induced dyskinesia: a historical review of Parkinson's disease, dopamine, and modern advancements in research and treatment.
Review in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Review
- The mitogenome mutation repertoire affects progression of Parkinson's Disease.Genetics and molecular biology · 2026Article
- Temporal Features of Gamma Activity of Hyper-direct Pathway Regulated by Dopamine Receptors in the Dyskinetic Rat.Neuroscience bulletin · 2026Article
- Design, Synthesis, Molecular Docking, Pharmacokinetic Properties, and Molecular Dynamics Simulation of Sulfonyl Derivatives of Benzimidazole against Parkinson's Disease.Current medicinal chemistry · 2026Article
- GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation.Drug design, development and therapy · 2026Review
- Synaptic Changes in Mice Lacking Alpha- and Gamma-Synucleins.Biomedicines · 2025Article
- Inefficacy of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease Patients with Levodopa-Induced Dyskinesias: Results from a Pilot Study.Biomedicines · 2025Article
- Application of Natural Products in Neurodegenerative Diseases by Intranasal Administration: A Review.Pharmaceutics · 2025Review
- Sexual Dimorphism in Levodopa-Induced Dyskinesia Following Parkinson's Disease: Uncharted Territory.The European journal of neuroscience · 2025Review
- "Unraveling the role ofReceptors (Basel, Switzerland) · 2025Article
- Electrophysiological Alterations in the Progression of Parkinson's Disease and the Therapeutic Effect of Tetrabenazine on Rats With Levodopa-Induced Dyskinesia.CNS neuroscience & therapeutics · 2025Article
- Patients' Preferences for Parkinson's Disease Pharmacotherapy: An Online Discrete Choice Experiment.Parkinson's disease · 2025Article
- Levodopa-induced dyskinesia: brain iron deposition as a new hypothesis.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024Review
- Construct, Face, and Predictive Validity of Parkinson's Disease Rodent Models.International journal of molecular sciences · 2024Review
- Deep brain stimulation for Parkinson's disease: systematic review with meta-analysis and trial sequential analysis.BMJ medicine · 2024Article
- Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia.Antioxidants (Basel, Switzerland) · 2023Article
- To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson's disease.NPJ Parkinson's disease · 2023Review
- Endophytic Fusarium species, a unique bioresource for disaggregator of misfolded alpha-synuclein.Archives of microbiology · 2023Article
- Heat-killedBioengineering & translational medicine · 2023Article
- Alzheimer's and Parkinson's disease therapies in the clinic.Bioengineering & translational medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Over the past two decades, animal models of Parkinson's disease (PD) have helped to determine the plausible underlying mechanism of levo-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia following L-DOPA treatment. However, our understanding of the mechanisms related to this phenomenon remains incomplete. The purpose of this manuscript is to provide a comprehensive review of treatment protocols used for assessing the occurrence of L-DOPA-induced dyskinesia, L-DOPA absorption, distribution, drug/food interaction, and discuss current strategies and future directions. This review offers a historical perspective using L-DOPA in animal models of PD and the occurrence of L-DOPA-induced dyskinesia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.